Aspire has introduced a licensed version of Bisoprolol 1mg/ml oral solution (sugar-free). At the same time, an unlicensed version of Bisoprolol 5mg oral solution was listed in Part VIII B of the Drug Tariff.

Since a UK-licensed product became available in August, the Department of Health and Social Care (DHSC) has updated the payment arrangements for prescriptions claimed during August 2025. Here’s what you need to know:

Prescribed productEndorsed asReimbursement for prescriptions dispensed in August 2025
Bisoprolol 5mg/5ml oral solutionAspire Pharma LtdReimbursement based on the UK list price of Aspire Pharma Ltd product

Bisoprolol 5mg/5ml oral solution

or

Bisoprolol 5mg/5ml oral solution sugar free

Endorsed as a Part VIIIB specialReimbursement based on August Drug Tariff Part VIIIB price
Bisoprolol 5mg/5ml oral solution (Drug Tariff Special Order)Endorsed as a Part VIIIB specialReimbursement based on August Drug Tariff Part VIIIB price.
Bisoprolol 5mg/5ml oral solution (Drug Tariff Special Order)Aspire Pharma LtdReimbursement based on August Drug Tariff Part VIIIB price.
Bisoprolol 5mg/5ml oral solution sugar free (Drug Tariff Special Order)Endorsed as a Part VIIIB specialReimbursement based on August Drug Tariff Part VIIIB price

Bisoprolol 1mg/ml oral solution sugar free

or

Bisoprolol 1mg/ml oral solution sugar free (Aspire Pharma Ltd)

Aspire Pharma LtdReimbursement based on the UK list price of Aspire Pharma Ltd product

Bisoprolol 1mg/ml oral solution

or

Bisoprolol 1mg/ml oral solution sugar free

No endorsement presentNHSBSA will contact the pharmacy to establish what was supplied and reimburse accordingly.
  • The adjustment will automatically be applied for August which contractors will see in their relevant payments, Bisoprolol 5mg/5ml oral solution & Bisoprolol 5mg/5ml oral suspension have since been removed from September 2025 Tariff  
  • If you have any questions about the Drug Tariff - Call Information Services on 0800 783 5709 option 2